Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Cardiotoxicity of antitumor therapy in children. Literature review
https://doi.org/10.33667/2078-5631-2025-14-20-25
Abstract
Relevance. Cardiotoxicity of antitumor therapy in children represents the important problem in pediatric oncology. In recent decades, due to the introduction of new treatment methods, there has been a significant increase in the survival rate of children with oncologic diseases, but cardiovascular complications developing during antitumor treatment become a frequent problem and have a serious impact on the quality of life of patients, as well as may increase the risks of lethal outcomes.
Objective. To review the existing data on cardiotoxicity resulting from the use of antitumor drugs in children, with emphasis on the mechanisms of its development, clinical manifestations, diagnostic methods, approaches to treatment and prevention.
Materials and Methods. When writing the literature review, data were analyzed in databases PubMed, Scopus, eLIBRARY devoted to the problem of cardiotoxicity of antitumor therapy in children for the period 2013–2024.
Conclusion. Cardiotoxicity remains an important and underestimated problem in pediatric oncology. Objective assessment of cardiovascular risk before, during and after chemotherapy, timely diagnosis of complications and implementation of cardioprotection methods can significantly improve the quality and duration of life of children with malignant diseases. Further research is needed to develop standardized protocols for screening and prevention of cardiotoxicity in these children.
About the Author
L. R. Turkiya
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Lana R. Turkiya, MD, cardiologist
Pediatric Oncology and Hematology Research Institute named after Academician of the Russian Academy of Sciences L. A. Durnov; Scientific and Consultative Department
Moscow
References
1. Aleskerova G. A., Shervashidze M. A., Popa A. V., Valiev T. T., Kurdjukov B. V., Batmanova N. A., Mentkevich G. L. Treatment Results of All IC-BFM 2002 Protocol in Children with Acute Lymphoblastic Leukemia. Onkopediatria. 2016; 3 (4): 302–308. (In Russ.).
2. Belyaeva E. S., Susuleva N. A., Valiev T. T. The importance of intensive chemotherapy for advanced Hodgkin lymphoma in children. Russian Journal of Woman and Child Health. 2020; 3 (2): 149–153. (In Russ.).
3. Valiev T. T., Morozova O. V., Kovrigina A. M., Makhonova L. A., Sholokhova E. N., Serebryakova I. N., Popa A. V., Tupitsyn N. N., Mentkevich G. L. Diagnosis and treatment of anaplastic large-cell lymphomas in children. Hematology and Transfusiology, 2012; 57 (1): 3–9. (In Russ.)
4. Baryakh E. A., Tyurina N. G., Vorobyov V. I., Gemdzhyan E. G., Mangasarova Yа.K., Klyasova G. A., Kovrigina A. M., Obukhova T. N., Zvonkоv E. E., Vernyuk M. A., Chervontseva A. M., Polyakov Yu. Yu., Misyurina A. E., Valiev T. T., Zherebtsova V. A., Magomedova A. U., Galstyan G. M., Yatskov K. V., Nesterova E. S., Vorobyov A. I. et al. (2015). Therapy for Burkitt’s lymphoma according to the BL–M-04 protocol: 12-year experience. Therapeutic Archive. 2015; 87 (7): 4–14. (In Russ.).
5. Vinogradova Yu.E., Lutsenko I. N., Kaplanskaia I. B., Vorob’ev I.A., Samoĭlova R. S., Gorgidze L. A., Ryzhikova N. A., Valiev T. T., Giliazitdinova E. A., Dzhulakian U. L., Egorova E. K., Zvonkov E. E., Krasil’nikova B.B., Magomedova A. U., Margolin O. V., Mar’in D.S., Kremenetskaia A. M., Kravchenko S. K., Vorob’ev A. I. Efficacy of therapy of different variants of anaplastic large t-cell lymphomas. Therapeutic Archive. 2008; 80 (7): 33–37. (In Russ.).
6. Baryakh E. A., Valiev T. T., Yatskov K. V., Zvonkоv E. E., Kremenetskaya A. M., Kravchenko S. K., Magomedova A. U., Galstyan G. M., Klyasova G. A., Drozhzhin A. A., Ryazanova I. B., Shulutko E. M., Obukhova T. N., Biryukova L. S., Shevelev A. A., Gretsov E. M., Gubkin A. V., Kaplanskaya I. B., Gotman L. N., Krasilnikova B. B. et al. Intensive therapy of Burkitt lymphoma: description of two clinical cases. Hematology and Transfusiology. 2007; 52 (1): 41–43. (In Russ.).
7. Valiyev T.T., Baryakh E. A. Evolution of concepts for diagnosis and treatment of Burkitt’s lymphoma. 2014; 7 (1): 46–56. (In Russ.).
8. Valiev T. T., Baryakh E. A., Zeynalova P. A., Kovrigina A. M., Kravchenko S. K., Obukhova T. N., Falaleeva N. A., Senderovich A. I., Serebryakova I. N., Kaminskaya I. V., Levashov A. S., Mentkevich G. L. Optimization of diagnosis and treatment of Burkitt lymphoma in children, adolescents and young adults. Clinical Oncohematology. Basic Research and Clinical Practice. 2014; 7 ( 2): 175–183. (In Russ.).
9. Zaeva G. E., Valiev T. T., Gavrilenko T. F. et al. Long-term effects of pediatric cancer therapy: 35-year clinical experience. Journal of Modern Oncology. 2015; 18 (1): 55–60. (In Russ.).
10. Gurieva O. D., Savelyeva M. I., Valiev T. T. Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review). Russian Journal of Pediatric Hematology and Oncology. 2021; 8 (4): 60–70. (In Russ.)
11. Valiev T. T., Shervashidze M. A., Belysheva T. S. Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-bfM 2002. Oncohematology. 2022; 17 (3): 137–59. (In Russ.).
12. Zamorano JL, Lancellotti P, Rodriguez Muñoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2016 Dec 24]. Eur Heart J. 2016; 37 (36): 2768–2801. doi: 10.1093/eurheartj/ehw211
13. Chazova I. E., Ageev F. T., Aksenova A. V., Vicenya M. V., Gilyarov M. Yu., Martynyuk T. V., Panchenko E. P., Poltavskaya M. G., Potievskaya V. I., Trofimova O. P., Fedotkina Yu. A. Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Eurasian heart journal. 2022; (1): 6–79. (In Russ.). doi: 10.38109/2225-1685-2022-1-6-79
14. Mavinkurve-Groothuis A.M., Kapusta L., Groot-Loonen J.J. et al. The role of biomarkers in assessment of cardiac toxicity in children. BMC Cancer. 2010; 10: article 519.
15. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015; 12 (11): 620. doi: 10.1038/nrcardio.2015.133
16. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013 Apr; 34 (15): 1102–11.
17. Lipshultz S. E., Cochran T. R., Franco V. I., Miller T. L. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat. Rev. Clin. Oncol. 2013; 10: 697–710.
18. Armenian S. H., Hudson M. M., Mulder R. L. et al. Surveillance guidelines for childhood cancer survivors. The Lancet Oncology. 2017; 18 (3): e145–e160.
19. Hudson M. M., Ness K. K., Gurney J. G. et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309 (22): 2371–2381.
20. Woiniak A, Drewa G, Woźniak B, Schachtschabel DO, Mila Kierzenkowska C, Drewa T. et al. The effect of antitumor drugs on oxidative stress in B 16 and S 91 melanoma cells in vitro. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2005; 11 (1): BR 2229. PMID: 15614186.
21. Belenkov Yu.N., Ershov V. I., Antyufeeva O. N., Budanova D. A., Kochkareva Yu.B., Gadaev I. Yu., Bochkarnikova O. V., Sokolova I. Ya., Kirichenko Yu. Yu. Assessment of the Role of Oxidative Stress Indicators and Early Markers of Myocardial Injury and Disfunction in Patients with Lymphoproliferative Diseases. Kardiologiia. 2019; 59 (8): 47–53. (In Russ.). DOI: 10.18087/cardio.2019.8.n682
22. Justin Floyd, DO, James P Morgan, MD, Ph D. Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER 2-targeted agents, and fluoropyrimidines.
23. Mahmood S. S. et al. Myocarditis with immune checkpoint inhibitors : A case series and systematic review. Circulation. 2018; 137 (18): 1791–1802.
24. Lefebvre B. et al. Cardiovascular toxicities associated with CAR-T cell therapy : A review of clinical data. J Am Coll Cardiol. 2021; 77 (21): 2721–2730.
25. Ladenstein R., Pötschger U., Valteau-Couanet D. et al. Interleukin 2 with anti-GD 2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018; 19 (12): 1617–1629.
26. Yu A. L., Gilman A. L., Ozkaynak M. F. et al. Anti-GD 2 antibody with GM–CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 2010; 363 (14): 1324–1334.
27. Kholodenko I. V., Kalinovsky D. V., Doronin I. I. et al. Neuroblastoma origin and therapeutic targets for immunotherapy. J. Immunol. Res. 2018, article ID 7394268.
28. U. S. Food and Drug Administration. Dinutuximab (Unituxin) Prescribing Information [Electronic resource]. 2015. URL: https://www.accessdata.fda.gov (дата обращения: 01. 05. 2025).
29. Lemieux J., Porter C. C., Voss S. D. et al. Cardiac monitoring during dinutuximab therapy: institutional experience and recommendations. Pediatr. Blood Cancer. 2018; 65 (9): e27247.
30. Curigliano G, Lenihan D, Fradley M. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020; 31 (2): 171–190. doi: 10.1016/j.annonc.2019.10.023
31. Belenkov Yu.N., Ilgisonis I. S., Kirichenko Yu. Yu., Murtuzaliev Sh. M. Cardio-oncology today: digest of the first European clinical guidelines (2022). Kardiologiia. 2023; 63 (7): 3–15. (In Russ.). doi: 10.18087/cardio.2023.7.n2445
32. Tromp J., Steggink L. C., Van Veldhuisen D. J., Gietema J. A., van der Meer P. Cardio-oncology. Progress in diagnosis and treatment of cardiac dysfunction. Clin Pharmacol Ther. 2017; 101 (4): 481–90. doi: 10.1002/cpt.614
33. Smita B. Children’s Hospital of Alabama, Birmingham, AL for her leadership in overseeing the initial development of the COG LTFU Guidelines as Chair of the COG Late Effects Committee, and for her continued oversight of all content in all versions of the COG LTFU Guidelines Version 6.0 – October 2023.
Review
For citations:
Turkiya L.R. Cardiotoxicity of antitumor therapy in children. Literature review. Medical alphabet. 2025;(14):20-25. (In Russ.) https://doi.org/10.33667/2078-5631-2025-14-20-25
Views:
48
Email this article 